iRGD-guided tamoxifen polymersomes inhibit estrogen receptor transcriptional activity and decrease the number of breast cancer cells with self-renewing capacity

BACKGROUND: Tamoxifen (Tam) is the most frequent treatment for estrogen receptor (ER) positive breast cancer. We recently showed that fibronectin (FN) leads to Tam resistance and selection of breast cancer stem cells. With the aim of developing a nanoformulation that would simultaneously tackle ER a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Nanobiotechnology
Autors principals: Diaz Bessone, María Inés, Simón-Gracia, Lorena, Scodeller, Pablo, Ramirez, María de los Angeles, Lago Huvelle, María Amparo, Soler-Illia, Galo J. A. A., Simian, Marina
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2019
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6898937/
https://ncbi.nlm.nih.gov/pubmed/31812165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12951-019-0553-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars